Jack Ogilvie, MD
Vascular & Interventional Radiology · Worthington, OHNPI 1467940684
Payments from drug & device makers
What this record shows
Boston Scientific accounts for 70.9% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2023 at $2,438 and has fallen 84.5% since, to $379 in 2025.
Across 39 payments — averaging $95.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$3K
- Bard Peripheral Vascular, Inc.$289
- Dendreon Pharmaceuticals LLC$238
- Johnson & Johnson$147
- Immunitybio, Inc.$88
- Laborie Medical Technologies Corp.$80
- plus $247 from 10 others
What the payments were for
- Travel & lodging$1,65944%
- Food & beverage$2,08256%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 10 | $2,653 |
| Bard Peripheral Vascular, Inc. | 2 | $289 |
| Dendreon Pharmaceuticals LLC | 7 | $238 |
| Johnson & Johnson(2 entities) | 2 | $147 |
| Immunitybio, Inc. | 3 | $88 |
| Laborie Medical Technologies Corp. | 3 | $80 |
| AbbVie | 2 | $59 |
| Sumitomo Pharma America, Inc. | 2 | $33 |
| Merck | 1 | $30 |
| Progenics Pharmaceuticals, Inc. | 1 | $26 |
| Cordis US CORP. | 1 | $22 |
| Accord Healthcare, Inc. | 1 | $21 |
| Tolmar, Inc. | 1 | $16 |
| Urogen Pharma, Inc. | 1 | $14 |
| Ferring Pharmaceuticals Inc. | 1 | $13 |
| Terumo Medical Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,741 in reported general payments places this provider in the 65th percentile of 125 vascular & interventional radiology providers in Ohio.
See all vascular & interventional radiology providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Methylprednisolone | 98 | $492 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 80 | $166 |
| Ibuprofen | 62 | $109 |
| Famotidine | 77 | $75 |
| Ciprofloxacin Hcl | 13 | $34 |
| IbuIbuprofen | 19 | $32 |
Paid to pharmacies, not to this prescriber.
Other vascular & interventional radiology in Worthington
- James McGrawColumbus$222K
- Fred MoesleinColumbus$205K
- Mamdouh KhayatColumbus$159K
- Charles MartinCleveland$122K
- Lucy la PernaColumbus$105K
- Seetharam ChadalavadaCincinnati$96K
- Deepak SudheendraDublin$57K
- Kamal MorarKettering$56K
- Michael ClineColumbus$35K
- Matthew SebastianToledo$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.